Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial

Eur Respir J. 2020 Feb 6;55(2):1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb.

Jennifer A Whitty^{1

2}, Jenny Rankin³, Dina Visca^{4

5

6}, Vicky Tsipouri^{5

6}, Letizia Mori^{5

6}, Lisa Spencer⁷, Huzaifa Adamali⁸, Toby M Maher⁶, Nicholas S Hopkinson⁶, Surinder S Birring⁹, Morag Farquhar¹⁰, Athol U Wells^{5

6}, Piersante Sestini¹¹, Elisabetta A Renzoni^{5

6}

¹ Norwich Medical School, University of East Anglia, Norwich, UK jennifer.whitty@uea.ac.uk.
² Collaboration for Leadership in Applied Health Research and Care (CLAHRC), East of England, UK.
³ Norwich Medical School, University of East Anglia, Norwich, UK.
⁴ Division of Pulmonary Rehabilitation, Istituti Clinic Scientifici Maugeri, IRCCS, Tradate, Italy.
⁵ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
⁶ National Heart and Lung Institute, Imperial College London, London, UK.
⁷ Liverpool Interstitial Lung Disease Service, Aintree Chest Centre, University Hospital Aintree, Liverpool, UK.
⁸ Bristol Interstitial Lung Disease (BILD) Service, Southmead Hospital, Bristol, UK.
⁹ Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences nd Medicine, King's College London, London, UK.
¹⁰ School of Health Sciences, University of East Anglia, Norwich, UK.
¹¹ Dept of Respiratory Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.

No abstract available

Publication types